Navigation Links
Cancer Research UK Signs Deal With Centella Therapeutics, Inc. to Launch Clinical Development of Radiotherapy-Enhancing Drug
Date:5/25/2011

PALO ALTO, Calif. and LONDON, May 25, 2011 /PRNewswire/ -- Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm – have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.  

CEN-209*, discovered at the Auckland Cancer Society Research Centre and exclusively licensed to Centella from Auckland Uniservices Ltd. of New Zealand, is designed to provide benefit when used together with radiotherapy and chemotherapy to treat solid tumours. CEN-209 is the seventh drug candidate to enter Cancer Research UK's Clinical Development Partnerships (CDP) scheme.  (See related press release: Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment, May 23, 2011).

CEN-209 has the potential to destroy the areas of tumours which are low in oxygen – or hypoxic. Tumour cells become hypoxic because the blood vessels supplying them with nutrients and oxygen are often weak, twisted and ineffective due to the rapid growth of the tumour.  

Cancer cells that are hypoxic are more resistant to chemotherapy and radiotherapy and often survive such treatment. By destroying the hypoxic part of tumours with CEN-209 in parallel to chemotherapy and radiotherapy, it is hoped that this combination treatment will be more effective.

CDP is a joint initiative between Cancer Research UK's Drug Development Office and Cancer Research Technology, to develop promising anti-cancer agents from companies that are not able to take them through early phase clinical trials themselves. The CDP scheme allows companies to retain the background rights to their programmes while enabling Cancer Research UK to take on early development work to assess if there is a potential benefit to ca
'/>"/>

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Colo. , July 23 2014 Ampio ... of its new headquarters, manufacturing and research facility: ... CO 80112 Direct: (720) 437-6500 ... labor efficient, pharmaceutical drug manufacturing facility will be fully ... produce the first batches of Ampion TM necessary ...
(Date:7/23/2014)... 2014 Pelvalon, Inc. is making its clinical ... Washington, D.C. with the presentation of ... Vaginal Bowel Control (VBC) System.  Holly E. Richter ... and Pelvic Reconstructive Surgery at the University of Alabama ... for Gynecological Surgeons (SGS), served as the National Principal ...
(Date:7/23/2014)... July 23, 2014 Research and ... "Emulsifiers - Global Strategic Business Report" ... http://photos.prnewswire.com/prnh/20130307/600769 This report analyzes ... and US$ Thousands by the following Product Segments: ... Polysorbates and Sorbitan Esters, and Polyglycin Polyricinoleate & ...
Breaking Medicine Technology:Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2Pelvalon Announces Results from the LIFE Pivotal Trial at the 2014 AUGS/IUGA Conference 2Emulsifiers - Global Strategic Business Report: Updated 2014 Report 2Emulsifiers - Global Strategic Business Report: Updated 2014 Report 3
... (Nasdaq: LMNX ) today announced that it expects ... Monday, April 30, 2012. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the first quarter ended March 31, ...
... FARMINGTON, Conn., April 9, 2012 /PRNewswire-iReach/ -- Global ... 3 significant Drug Discovery and Healthcare conferences scheduled for Boston, ... CHI and Bio-IT World,s 12th Annual Structure-Based Drug Design Conference ... Structure-based drug design took nearly two decades to arrive at ...
Cached Medicine Technology:Luminex Corporation First Quarter Earnings Release Scheduled for April 30, 2012 2Luminex Corporation First Quarter Earnings Release Scheduled for April 30, 2012 3Boston to Host 3 Major Annual Drug Discovery Conferences, Early Bird Expiring April 27 2Boston to Host 3 Major Annual Drug Discovery Conferences, Early Bird Expiring April 27 3
(Date:7/23/2014)... World Gardens Café, the premier provider ... cuisine, received rave reviews last week when it gave ... attendees were amazed that healthy food could taste so ... Café, the premier provider of delicious and flavorful home-delivered ... Dave Linden’s LA’s Largest Mixer. Attendees who stopped by ...
(Date:7/23/2014)... Sanuvox has produced a six minute ... company’s latest system designed for hospital surface disinfection. ... a primary and secondary unit to eliminate shadows ... controlling (6 log reduction) drug-resistant microorganisms such as ... minutes in a standard patient hospital room. The ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Low ... state-run insurance exchanges to come up with alternative ... of the myriad ways to accomplish this in ... Inside Health Insurance Exchanges (HEX). , “We never ... for state-run exchanges, Christopher Condeluci, an attorney at ...
(Date:7/23/2014)... MA (PRWEB) July 23, 2014 ... medical education to a community of more than 260,000 ... Medicine Ultrasound Institute will launch a national continuing medical ... care clinicians about new advancements in ultrasound and how ... Pri-Med and the University of South Carolina School of ...
(Date:7/23/2014)... 23, 2014 TeraGanix has recently ... Grande, Arizona, located only 4.5 miles off of highway I-8. ... convenience and accessibility for businesses in the Arizona region that ... crops. , Its Casa Grande location is only 1 hour ... one hour from Phoenix. With over 26 million acres ...
Breaking Medicine News(10 mins):Health News:Healthy Food Gets Rave Reviews at LA’s Largest Mixer 2Health News:Sanuvox Produces ASEPTIX² Movie Showcasing the Feature Benefits of the Company’s Latest Flagship Hospital Surface Disinfection System 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 3Health News:Pri-Med and the University of South Carolina School of Medicine Launch National Ultrasound Education Initiative for Primary Care Clinicians 2Health News:Pri-Med and the University of South Carolina School of Medicine Launch National Ultrasound Education Initiative for Primary Care Clinicians 3Health News:TeraGanix Opens New Arizona-Based Agricultural Products Supply Facility 2Health News:TeraGanix Opens New Arizona-Based Agricultural Products Supply Facility 3
... in the journal of Minerva Cardioangiologica reveals Pycnogenol, pine ... jetlag in passengers by nearly 50 percent. The two-part ... scoring system, showed Pycnogenol lowered symptoms of jetlag such ... both healthy individuals and hypertensive patients. Passengers also experienced ...
... Ignagni, President,and CEO of America,s Health Insurance Plans ... Obama:, "We congratulate President-elect Barack Obama for ... for health care reform, and we look forward ... Congress to develop,workable solutions to the health care ...
... found , , WEDNESDAY, Nov. 5 (HealthDay News) -- Researchers ... to eliminate memory problems in mice with the rodent ... no way to know if the treatment will have ... enroll Alzheimer,s patients in a new study, and scientists ...
... 5 The American,Nurses Association (ANA) congratulates President-Elect ... to working with the new administration,and new lawmakers ... patients we,serve., President-Elect Barack Obama has been ... state senator, and as a U.S. Senator,Barack Obama ...
... 5 & 1 Plan, OWINGS MILLS, Md., Nov. ... portion-controlled weight-loss program, today,announced the launch of its newest ... formula that is lower in calories, total fat, and,carbohydrates. ... Crunch, and Caramel Crunch, and are available at, http://www.choosemedifast.com/ ...
... look forward to health system reform in 2009, ... Nancy Nielsen, M.D., AMA President:, "The American Medical ... the presidency of the United States. He has,proposed a ... made it a,central issue in his campaign., "The ...
Cached Medicine News:Health News:Study shows pine bark reduces jetlag 2Health News:Study shows pine bark reduces jetlag 3Health News:Vitamin Holds Promise for Alzheimer's Disease 2Health News:Medifast Adds New Crunchy Bars to Product Line 2Health News:AMA Congratulates President-Elect Obama 2
... The Veris physiological monitor offers a comprehensive ... specifically designed for pediatric and neonate patients, ... to 3T. Veris is the first MR ... of pediatric and neonate patient monitoring. The ...
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
... is a fully automated ... for clotting, photometric and ... tests.The medium-throughput analyser offers ... tubes, 45 reagents onboard, ...
Medicine Products: